INSIGHT FOR EYESIGHT – Novel mRNA medicines for eye disease

Project description

Pioneering mRNA therapy could promote healing and reduce loss of vision

Messenger RNA (mRNA) plays a pivotal role in gene expression. During transcription, the code carried in DNA is copied to a single strand of mRNA. The mRNA is then used as a template to assemble the appropriate sequence of amino acids into the protein. INSIGHT EU has developed a proprietary mRNA-delivery platform that is already being used to treat chronic kidney disease. The project has now turned its sights to treatments for impaired vision and blindness. Development of mRNA therapies delivered to the eye could promote healing and ameliorate vision loss. Success could open a new window on life for millions with impaired vision.

Fields of science

• medical and health sciences › basic medicine › pharmacology and pharmacy › drug discovery
• medical and health sciences › clinical medicine › ophthalmology › glaucoma
• medical and health sciences › clinical medicine › surgery
• medical and health sciences › clinical medicine › ophthalmology › retinopathy
• natural sciences › biological sciences › genetics › RNA

Programme(s)

• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme
• H2020-EU.2.3.2.2. - Enhancing the innovation capacity of SMEs

Topic(s)

• INNOSUP-02-2019-2020 - European SME innovation Associate - pilot

Call for proposal

H2020-INNOSUP-2018-2020

See other projects for this call

Sub call

H2020-INNOSUP-2019-02

Funding Scheme

CSA - Coordination and support action

Coordinator

MERCURNA BV

Net EU contribution

€ 75 937,50

Address

Geurdeland 17g
6673 DR Andelst
Netherlands

Region

Oost-Nederland › Gelderland › Arnhem/Nijmegen

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Other funding

€ 0,00